Security Snapshot

Kiniksa Pharmaceuticals International, plc - Common Stock (KNSA) Institutional Ownership

CUSIP: G52694109

13F Institutional Holders and Ownership History from Q2 2024 to Q3 2026

13F reference period

Q2 2026

Institutions Reporting

265

Shares (Excl. Options)

46.94MFull value: 46,936,395 · shares · 30 Jun 2026

Price

$63.95

The headline uses the Q2 2026 reference period after its reporting deadline. Available reports may still be incomplete or amended. Newer periods in the history table contain incoming reports and may be incomplete.

Save this security page for your next review

Watchlists follow companies and investors, across their share classes. Bookmark this page to revisit this specific CUSIP and its quarterly holders. If you create an account from here, we will bring you back after verification.

Latest holder snapshot 5 signals
Portfolio coverage rank
0%
Share change
+1,669,247
Value change
+$125,527,864
Number of holders
265
Issuer context Names, identifiers, and filing context for this profile. 3 identity fields
Shares outstanding
46,087,073
SEC-reported price per share
$74.61
Insider filing price
$74.61
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Filing notes and source

Key facts

  • KNSA - Kiniksa Pharmaceuticals International, plc - Common Stock is tracked under CUSIP G52694109.
  • 265 institutions reported positions in Q2 2026.
  • 6 significant owners is listed from Schedule 13D/13G reporting.

Change

  • Holder count moved from 226 to 265 between Q1 2026 and Q2 2026.
  • SEC-reported value moved from
    $2.18BFull value: $2,181,913,275 · USD · 31 Mar 2026
    to
    $2.99BFull value: $2,992,781,887 · USD · 30 Jun 2026
    .

Research use

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Evidence

Source: SEC Form 13F

Latest holder context comes from 265 institutions filings for Q2 2026.

Open SEC evidence

Security key

G52694109

13F reference period

Q2 2026

13F holders

265

13D/G owners

6

CIK / CUSIP context first

13D/G owners

Significant owners

Large-stake holder rows connected to Schedule 13D/G evidence.

Rows
6
Security
KNSA
Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
FMR LLC 15% +38% $326,692,012 +$93,051,943 6,787,700 +40% FMR LLC 31 Mar 2026
Rubric Capital Management LP 7.4% -21% $139,836,713 -$24,414,238 3,328,653 -15% Rubric Capital Management LP 31 Dec 2025
BAKER BROS. ADVISORS LP 7% $140,056,330 3,253,341 Julian C. Baker 21 May 2026
VANGUARD GROUP INC 7% $118,941,532 3,063,135 The Vanguard Group 30 Sep 2025
BlackRock, Inc. 5.5% +450% $162,099,757 +$135,359,000 2,534,789 +506% BlackRock, Inc. 30 Jun 2026
TANG CAPITAL MANAGEMENT LLC 5.2% $46,556,874 2,178,609 TANG CAPITAL MANAGEMENT, LLC 28 Mar 2025
As of 30 Jun 2026, 265 institutional investors reported holding
46.94MFull value: 46,936,395 · shares · 30 Jun 2026
shares of Kiniksa Pharmaceuticals International, plc - Common Stock (KNSA). This represents 102% of the company’s total
46.09MFull value: 46,087,073 · shares · Stored outstanding share count
outstanding shares.

13F concentration

Top 25 institutional shareholders

Largest 13F positions for this security by reported shares and value.

Top holder share
75%
Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
FMR LLC 15% 6,971,361 +2.2% 0.02% $445,818,527
Rubric Capital Management LP 8.7% 3,999,800 +6.7% 2.3% $255,787,210
BAKER BROS. ADVISORS LP 6.2% 2,834,643 +0.3% 0.91% $181,275,420
BlackRock, Inc. 5.9% 2,739,615 +463% 0% $175,198,378
TANG CAPITAL MANAGEMENT LLC 4.9% 2,259,889 0% 6.6% $144,519,902
VANGUARD PORTFOLIO MANAGEMENT LLC 4.1% 1,911,335 +8.2% 0.01% $122,229,873
VANGUARD CAPITAL MANAGEMENT LLC 3% 1,360,840 +2.1% 0% $87,025,718
MORGAN STANLEY 2.2% 1,011,143 +1.3% 0% $64,662,626
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP 2.1% 957,514 +7.3% 0.03% $61,233,020
Spruce Street Capital LP 2% 918,070 +21% 12% $58,710,577
DIMENSIONAL FUND ADVISORS LP 1.9% 874,786 +7.7% 0.01% $55,937,333
Invesco Ltd. 1.7% 772,806 +2694% 0% $49,420,945
Driehaus Capital Management LLC 1.6% 718,199 +17% 0.27% $45,928,826
STATE STREET CORP 1.5% 704,194 +819% 0% $45,033,206
ACADIAN ASSET MANAGEMENT LLC 1.5% 679,083 -49% 0.05% $43,409,000
Point72 Asset Management, L.P. 1.4% 659,493 +2.9% 0.06% $42,174,577
RICE HALL JAMES & ASSOCIATES, LLC 1.4% 624,928 +2.7% 1.9% $39,964,146
Pictet Asset Management Holding SA 1.3% 608,650 -2.3% 0.04% $38,923,168
GEODE CAPITAL MANAGEMENT, LLC 1.3% 604,180 +1263% 0% $38,633,635
Jupiter Topco LLC 1.3% 586,177 0% 0.02% $37,472,380
Connor, Clark & Lunn Investment Management Ltd. 1.2% 572,598 -12% 0.07% $36,617,642
D. E. Shaw & Co., Inc. 1.2% 569,756 -41% 0.02% $36,435,896
TWO SIGMA INVESTMENTS, LP 1.2% 561,480 +33% 0.03% $35,906,646
ALLIANCEBERNSTEIN L.P. 1.2% 556,151 -7.1% 0.01% $26,778,671
VICTORY CAPITAL MANAGEMENT INC 1.1% 504,853 -0.33% 0.02% $32,285,350

Quarter history

Institutional holders across reporting periods

Holder count, reported shares/value, and median price by quarter.

Periods
10
Headline period
Q2 2026
Rows shown
1-10 of 10
Period 13F Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2026 Q3 626,140 $46,863,211 +$2,558,651 $74.61 53
2026 Q2 46,936,395 $2,992,781,887 +$125,527,864 $63.95 265
2026 Q1 45,404,596 $2,181,913,275 +$142,639,064 $48.15 226
2025 Q4 42,953,248 $1,771,666,340 +$79,894,259 $41.25 222
2025 Q3 40,790,628 $1,583,711,476 +$42,923,169 $38.83 200
2025 Q2 39,765,765 $1,100,293,484 +$3,474,538 $27.67 186
2025 Q1 39,936,950 $887,052,494 +$25,344,007 $22.21 173
2024 Q4 38,910,834 $769,756,202 -$20,642,445 $19.78 156
2024 Q3 39,503,444 $987,347,556 +$124,891,730 $24.99 172
2024 Q2 35,248,812 $658,014,093 +$655,780,340 $18.67 126
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .